Pharmeasy had to choose between selling its recent acquisition, Thyrocare, or stifling its investors that have been with it for the last 8 years. It chose the latter.
Get full access to Boring Money at boringmoney.in/subscribe
Information
- Show
- FrequencyUpdated twice weekly
- Published19 July 2023 at 02:03 UTC
- Length9 min
- RatingClean